Skip to main content

Development and Validation of a Stability-Indicating HPLC Method for Determination of Bromocriptine Mesylate in Bulk Drug and Tablets

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

A simple, rapid and sensitive RP-HPLC method was developed and validated for the quantification of bromocriptine mesylate in bulk drug and tablet formulation. The separation was achieved on a Zorbax Eclipse XDB-C18 column (150 mm x 4.6 mm i.d.). The mobile phase consisted of methanol and 20 mM sodium acetate, pH 5 (70:30, v/v) at a flow rate of 1.5 mL min-1 and detection was performed at 300 nm using photodiode array (PDA) detector. The drug was subjected to various ICH prescribed stress conditions including hydrolysis (neutral, acid and alkaline), oxidation, photolysis and thermal degradation. The drug in solution was found to degrade significantly in alkaline hydrolysis and when exposed to sunlight. The proposed method was validated with respect to specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), stability, and robustness as per ICH guideline. The peak purity achieved from PDA detector and satisfactory resolution between drug and its degradants established the specificity of the method. The developed method was found to be successively applied for the quality control of bromocriptine mesylate in bulk drug and tablets as well as the stability indicating studies.

Keywords: Bromocriptine mesylate; Bulk drug; Forced degradation; LOD; LOQ; RP-HPLC; Stability-indicating method; Tablets; Validation; acid

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/157341213804806106

Publication date: February 1, 2013

More about this publication?
  • Current Pharmaceutical Analysis publishes authoritative reviews, written by experts in the field on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
ben/cpa/2013/00000009/00000001/art00013
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more